Skip to content

Effect of ingestion of trial supplement on sleep. A randomized, placebo controlled, double blind, cross-over study

Effect of ingestion of trial supplement on sleep. A randomized, placebo controlled, double blind, cross-over study - Effect of ingestion of trial supplement on sleep

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022069
Enrollment
60
Registered
2016-04-28
Start date
2016-05-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subject

Interventions

Trial supplement (4 days) - washout period - placebo (4 days) Placebo (4 days) - washout period - trial supplement (4 days)

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Japanese males and females aged from 20 to less than 65 years old. 2) Subjects who are weekday workers 3) Global score of Pittsburgh Sleep Quality Index-Japanese version is more than 6. 4)Subjects who can understand the detail of this study and decide to attend the study.

Exclusion criteria

Exclusion criteria: 1) Subjects who are routinely use the health food, dietary supplement, and medicine including over-the-counter drug for improving of sleep or fatigue. 2) Subjects with excessive alcohol-drinking behaviors. 3) Subjects who cannot stop drinking alcohol during study period I and II 4) Subjects who are under the medication, counseling, or exercise therapy. 5) Subjects who have under treatment or history of disease such as diabetes, liver disease, kidney disease, heart disease, adrenal cortex disease. 6) Subjects who have under treatment or a history of sleep apnea syndrome or is suspected of sleep apnea syndrome. 7) Night and day shift worker or manual laborer 8) Working days and holidays are irregular 9) Subjects who have mental illness or insomnia. 10) Subjects who will use medicine for Perennial allergic rhinitis in study period. 11) Heavy smoker 12) Subjects having possibilities for emerging allergy related to the study foods. 13) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating. 14) Subjects who have heavy menstrual cramps and premenstrual syndrome. 15) Subjects who are planned to participate in other clinical study 16) Subjects who are judged as unsuitable for the study by the investigator for other reason

Design outcomes

Primary

MeasureTime frame
OSA sleep inventory MA version

Secondary

MeasureTime frame
Sleep electroencephalogram, POMS 2 brief form, visual analogue scale (VAS) for fatigue, VAS for daytime sleepiness

Countries

Japan

Contacts

Public ContactEiji Yoshikawa

KSO Corporation Sales department

yoshikawa@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026